Oncolytics Biotech is trading 5.4% up at $0.84, with the move most consistent with broader risk appetite.
- Biotechnology is up 2.02%, while major U.S. indexes are also higher.
- No clearly reported company-specific announcement was identified on August 21, 2026.
- The latest notable news was the August 18 FDA alignment on a potential pivotal REO 033 colorectal-cancer study expansion; it may support sentiment, but sources do not directly attribute today’s gain to it.